VIRTUAL SESSIONS ARE NOT LIVE STREAMED. THEY WILL BE RECORDED AND PUBLISHED LATER FOR VIEWING.
Saturday, October 12th
6:45am - 7:45am
CME Breakfast Symposium:
Optimizing ICI-Based Therapies for Patients with Advances Melanoma
Supported by Bristol Myers Squibb
7:00am - 5:00pm
Registration Open
8:00am-10:35am
Plenary Session 5
Molecular Biology, Plasticity, & Heterogeneity
Chair: Robert Judson-Torres
8:00am - 8:20am
The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma
Ian Watson
8:20am - 8:35am
Physical confinement governs phenotypic plasticity in melanoma
Miranda Hunter
8:35am - 8:50am
ALDH1A3-acetaldehyde metabolism potentiates transcriptional heterogeneity in melanoma
Liz Patton
8:50am - 9:10am
The genomic evolution and molecular underpinnings of tumor adaptability
Rachel Belote
9:10am - 9:30am
Uncovering Minimal Pathways in Melanoma Initiation
Anand Ganesan
9:30am - 9:45am
Loss of AMBRA1 mediates MAPK inhibitors resistance in melanoma by activating focal adhesion kinase 1 (FAK1)
Daniela De Zio
9:45am - 10:00am
Cell type-dependent roles in melanoma initiation: differing roles of epidermal and mesenchymal Midkine
Nuria Gago-Lopez
10:00am - 10:15am
Characterization of the BRAF Interactome Reveals BRAFV600E/p53WT Interaction
Kayla O’Toole
10:15am - 10:35am
Epigenetic regulators of melanoma initiation and progression: from human genetics to zebrafish models
Charles Kaufman
10:35am - 10:55am
Refreshment Break
10:55am - 12:35pm
Concurrent Session 6A
Melanoma Models & Melanocyte Biology
Chair: Elizabeth Patton
10:55am - 11:15am
Opportunities and challenges in melanoma patient derived organoids
Xiaowei Xu
11:15am - 11:30am
The role of aging in promoting immune mediated reactivation from metastatic dormancy
Mitchell Fane
11:30am - 11:45am
Melanin-Dependent and -Independent Functions of Mc1r in Melanomagenesis
Valentina Posada
11:45am - 12:00pm
Desmosome mutations in the microenvironment regulate melanoma proliferation
Mohita Tagore
12:00pm - 12:15pm
XPC-loss-of-function triggers melanomagenesis through CDKN2A downregulation
Vipin Shankar Chelakkot
12:15pm - 12:35pm
Embryonic gene module re-expression in melanoma yields insights into a Hdac2-driven mechanism of plastic adaptation
Kerrie Marie
10:55am - 12:35pm
Concurrent Session 6B
Impact of Host & Lifestyle Factors (Microbiome, Diet, Exercise)
Chair: Jennifer McQuade
10:55am - 11:15am
Leveraging the gut microbiome for melanoma treatment
Saman Maleki
11:15am - 11:30am
Human-to-mouse fecal microbiota transplant (FMT) to investigate the impact of high-fiber dietary intervention (HFDI) induced changes on the microbiome on response to immune checkpoint blockade (ICB).
Yufan Qiu
11:30am - 11:45am
Diet and Nutrition in Melanoma: An Analysis of the National Health and Nutrition Examination Survey (NHANES) in the United States
Hannah Verma
11:45am - 12:00pm
Real-world safety and clinical outcomes of nivolumab (NIVO) monotherapy (mono) or NIVO plus ipilimumab (NIVO+IPI) for pediatric patients (pts) with melanoma
Andrew Klink
12:00pm - 12:15pm
Sex-dependent effects in the aged melanoma tumor microenvironment influence metastasis and therapeutic responses
Yash Chhabra
12:15pm - 12:35pm
Exercise mediated changes in the melanoma immune microenvironment
Keri Schadler
12:35pm - 2:00pm
Lunch - Exhibit and Poster Viewing
12:45pm - 1:45pm
CME Lunch Symposium:
Exploring Oncolytic Virus Therapy for Anti-PD1-Failed Melanoma
Supported by Replimune, Inc.
2:00pm - 3:30pm
Plenary Session 7
Diversity and Inclusion in Melanoma Research
Chairs: Vito Rebecca & Jessie Villanueva
2:00pm - 2:15pm
A rising tide to lift all boats requires us to look beneath the surface
Eric Le-Lau
2:15pm - 2:30pm
Women in Cancer Research: Ensuring our Future, Sharing Lessons and Intentional Solutions
Lynn Schuchter
2:30pm - 3:30pm
Interactive Discussion
Panel
3:30pm - 4:00pm
Refreshment Break
4:00pm - 5:45pm
Concurrent Session 8A
Melanoma Genomics, Epigenomics, & Beyond
Chair: Hunter Shain
4:00pm - 4:20pm
tRNA epitranscriptomics: a new vulnerability in melanoma
Pierre Close
4:20pm - 4:35pm
Epigenetic characterization of melanomas from distinct histological subtypes.
Rong Ma
4:35pm - 4:55pm
RNA-targeting therapy to inhibit MAPK-signaling associated regulators
Susana Ortiz-Urda
4:55pm - 5:10pm
Prognostic Melanoma Subtypes Based on Deconvoluted Tumor- and Tumor Microenvironment-Specific Gene Expression Signatures
Allison Reiner
5:10pm - 5:25pm
The genomic landscape of melanoma-prone skin
Mitchell Stark
5:25pm - 5:45pm
microRNAs as a classifier of Acral Melanoma
Dekker Deacon
4:00pm - 5:45pm
Concurrent Session 8B
Adjuvant and Neoadjuvant Therapy
Chair: Hussein Tawbi
4:00pm - 4:20pm
What does neoadjuvant efficacy tell us about immunotherapy versus targeted efficacy across disease stages?
Keith Flaherty
4:20pm - 4:35pm
A tumor-informed plasma next-generation sequencing ctDNA assay to enhance monitoring of high-risk melanoma.
Meghan Mooradian
4:35pm - 4:55pm
Personalization of neoadjuvant immunotherapy in melanoma
Minke Lucas
4:55pm - 5:10pm
Concordance of Pathologic Response Assessment Between Investigator and Central Review: An Analysis of KEYMAKER-U02 Substudy 02C
Michael Tetzlaff
5:10pm - 5:25pm
Vibostolimab Coformulated With Pembrolizumab vs Pembro Alone as Adjuvant Therapy for High-Risk Melanoma: Results of the Phase 3 KEYVIBE-010 Study
Georgina Long
5:25pm - 5:45pm
Neoadjuvant translational research platform to predict, monitor and enhance response to immunotherapy
Ines Da Silva
7:00pm - 11:00pm
Awards Ceremony